-
InVitae Analyst: Acquisition Beefs Up Company's Hereditary Cancer Testing Capacity
Friday, July 12, 2019 - 11:31am | 332Read More...After purchasing Singular Bio in June, InVitae Corp (NYSE: NVTA) now plans to acquire Jungla, which would add to its hereditary cancer testing capabilities, according to Benchmark. The Analyst Bruce Jackson maintained a Buy rating on InVitae and raised the price target to $26. The Thesis InVitae...
-
Why You Shouldn't Be Concerned By Aratana's Shareholder Lawsuit
Tuesday, February 7, 2017 - 3:19pm | 492Read More...A shareholder lawsuit was filed against Aratana Therapeutics Inc (NASDAQ: PETX) after the company’s announcement Monday that the release of Entyce, an appetite stimulant for dogs, would be delayed until late 2017. Aratana’s stock dropped about 19 percent after the news about Entyce...
-
Positive News For BioTelemetry Courtesy Of Blue Cross Blue Shield; Shares Up 15%
Wednesday, October 5, 2016 - 10:13am | 387Read More...Lake Street has reiterated its Buy rating and $24 price target on BioTelemetry, Inc. (NASDAQ: BEAT), saying that the Anthem Blue Cross Blue Shield covering Mobile Cardiac Telemetry (MCT) is a positive for the company. Anthem Blue Cross Blue Shield now covers MCT for its roughly 36 million...
-
Lake Street Says Buy-Rated Tesaro Holds An Attractive Portfolio Of Cancer Therapies
Tuesday, September 6, 2016 - 2:10pm | 241Read More...Lake Street reaffirmed its Buy rating on TESARO Inc (NASDAQ: TSRO) given its launch of VARUBI (rolapitant). Varubi is an NK1 receptor antagonist for delayed Chemotherapy-Induced Nausea & Vomiting (CINV), with peak sales potential well in excess of $500 million, and total available market of...
-
Aratana's Drug Pipeline Suggests Revenue Growth Could Continue For Years
Tuesday, September 6, 2016 - 12:33pm | 350Read More...Bruce Jackson of Lake Street assumes coverage of Aratana Therapeutics Inc (NASDAQ: PETX) with a Buy rating and $15 target price, saying twelve additional new products in the pipeline suggest the revenue growth can continue for the next several years. The analyst expects more than $200 million in...
-
EnteroMedics is Favorite Idea for 2014 by Lake Street
Friday, January 3, 2014 - 12:43pm | 237Read More...In a report published Friday, Lake Street Capital Markets analyst Bruce Jackson rated EnteroMedics (NASDAQ: ETRM) as the favorite idea for 2014. Jackson reported that EnteroMedics if the best positioned to benefit from several near-term trends. The analyst commented, “First, the current macro...
